Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target

Chardan Capital maintained their Buy rating on Dyne Therapeutics's stock with a price target of $38.00.The price target implies an upside of 134.4% from the Sep 29 close of $16.21.Key takeaways from the analyst notePromising Clinical Data: Dyne Therapeutics has reported significant improvements in…